Expression of stromelysin-1 (MMP-3), gelatinase B (MMP-9), and plasminogen activator system during fetal calvarial development

Histopathology

Volumn 44, Issue 4, 2004, Pages 360-366

  Zeitler, P ^a   Pahnke, J ^a   Marx, A ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Calvarial sutures; Craniosynostosis; Matrix metalloproteinases; Plasminogen; Urokinase; Urokinase receptor

Indexed keywords

COLLAGEN TYPE 5; FIBRONECTIN; GELATINASE B; PLASMINOGEN ACTIVATOR; PROTEINASE; STROMELYSIN; UROKINASE; UROKINASE RECEPTOR;

APOPTOSIS; ARTICLE; BONE DEVELOPMENT; CALVARIA; CELL PROLIFERATION; CONNECTIVE TISSUE; CONTROLLED STUDY; ENZYME SPECIFICITY; FETUS; FETUS DEVELOPMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EXTRACELLULAR MATRIX; HUMANS; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; PLASMIN; RECEPTORS, CELL SURFACE; SKULL; URINARY PLASMINOGEN ACTIVATOR;

EID: 1842855313     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2004.01854.x     Document Type: Article

References (27)

1. Moss ML. Experimental alteration of sutural area morphology. Acta Anat. (Basel) 1957; 127; 569-590.
2. Decker JD, Hall SH. Light and electron microscopy of the new born sagittal suture. Anat. Rec. 1985; 212; 81-89.
3. Cohen M. Sutural biology and the correlates of craniosynostosis. Am. J. Med. Genet. 1993; 47; 581-616.
4. Renier D, Sainte-Rose C, Marchac D, Hirsch JF. Intracranial pressure in craniosynostosis. J. Neurosurg. 1982; 57; 370-377.
5. Furtwängler JA, Hall SH, Koskinen-Moffett LK. Sutural morphogenesis in the mouse calvaria. The role of apoptosis. Acta Anat. 1985; 124; 74-80.
6. Rice DP, Kim HJ, Thesleff I. Apoptosis in murine calvarial bone and suture development. Eur. J. Oral Sci. 1999; 107; 265-275.
7. Opperman LA, Adab K, Gakunga PT. Transforming growth factor-beta 2 and TGF-beta 3 regulate fetal rat cranial suture morphogenesis by regulating rates of cell proliferation and apoptosis. Dev. Dyn. 2000; 219; 237-247.
8. Globus RK, Doty SB, Lull JC, Holmuhamedov E, Humphries MJ, Damsky CH. Fibronectin is a survival factor for differentiated osteoblasts. J. Cell Sci. 1998; 111; 1385-1393.
9. Birkedal-Hansen H, Moore WGI, Bodden MK et al. Matrix metalloproteinases: a review. Crit. Rev. Oral Biol. Med. 1993; 4; 197-250.
10. Reponen P, Sahlberg C, Munaut C, Thesleff I, Tryggvason K. High expression of 92-kD type IV collagenase (Gelatinase B) in the osteoclast lineage during mouse development. J. Cell Biol. 1994; 124; 1091-1102.
11. Yang JN, Allan EH, Anderson GI, Martin TJ, Minkin C. Plasminogen activator system in osteoclasts. J. Bone Miner. Res. 1997; 12; 761-768.
12. Bord S, Horner A, Hembry RM, Compston JE. Stromelysin-1 (MMP-3) and stromelysin-2 (MMP-10) expression in developing human bone: potential roles in skeletal development. Bone 1998; 23; 7-12.
13. Davis BA, Sipe B, Gershan LA et al. Collagenase and tissue plasminogen activator production in developing rat calvariae: normal progression despite fetal exposure to microgravity. Calcif. Tissue Int. 1998; 63; 416-422.
14. Kusano K, Miyaura C, Inada M et al. Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology 1998; 139; 1338-1345.
15. Breckon JJW, Hembry RM, Reynolds JJ, Meikle MC. Matrix metalloproteinases and TIMP-1 localization at sites of osteogenesis in the craniofacial region of the rabbit embryo. Anat. Rec. 1995; 242; 177-187.
16. Häckel C, Radig K, Röse I, Roessner A. The urokinase plasminogen activator (u-PA) and its inhibitor (PAI-1) in embryo-fetal bone formation in the human: an immunohistochemical study. Anat. Embryol. 1995; 192; 363-368.
17. Miles LA, Plow EF. Plasminogen receptors: ubiquitous sites for cellular regulation of fibrinolysis. Fibrinolysis 1988; 2; 61-71.
18. Vassali JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J. Clin. Invest. 1991; 88; 1067-1072.
19. Jones PA, DeClerck YA. Destruction of extracellular matrices containing glycoproteins, elastin, and collagen by metastatic human tumor cells. Cancer Res. 1980; 40; 3222-3227.
20. Moser TL, Enghild JJ, Pizzo SV, Stack MS. The extracellular matrix proteins laminin and fibronectin contain binding domains for human plasminogen and tissue plasminogen activator. J. Biol. Chem. 1993; 268; 18917-18923.
21. Tryggvason K, Hoyhtya M, Salo T. Proteolytic degradation of extracellular matrix in tumor invasion. Biochim. Biophys. Acta 1987; 907; 191-217.
22. Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991; 5; 2145-2154.
23. Obata K, Iwata K, Okada Y et al. A one-step sandwich immunoassay for human matrix metalloproteinase 3 (stromelysin-1) using monoclonal antibodies. Clin. Chim. Acta 1992; 211; 59-72.
24. Nomura H, Fujimoto N, Seiki M, Mai M, Okada Y. Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas. Int. J. Cancer 1996; 69; 9-16.
25. Pyke C, Ralfkiaer E, Ronne E, Hoyer-Hansen G, Kirkeby L, Dano K. Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology 1994; 24; 131-138.
26. Jahkola T, Toivonen T, von Smitten K, Virtanen I, Wasenius VM, Blomqvist C. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors. Br. J. Cancer 1999; 80; 167-174.
27. Rice DP, Kim HJ, Thesleff I. Detection of gelatinase B expression reveals osteoclastic bone resorption as a feature of early calvarial bone development. Bone 1997; 21; 479-486.